Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC. This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles. We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients \>18 years old with a confirmed diagnosis of SCD. 2. Presenting with a VOC. 3. NPRS \>5 4. Willingness to participate and provide willing to sign a consent form. Who Should NOT Join This Trial: 1. Patient requiring specialized IVF management as per the treating physician discretion. 2. Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure 3. Patients with ESRD on chronic dialysis 4. Patients with signs of shock (low SBP \<100 or MAP \< 65) and signs of hypo perfusion 5. Known or suspected pregnancy 6. Previously enrolled in this trial within the last 30 days 7. Enrolled in another trial study that interfered with fluid management 8. Unable to obtain IV access. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients \>18 years old with a confirmed diagnosis of SCD. 2. Presenting with a VOC. 3. NPRS \>5 4. Willingness to participate and provide informed consent. Exclusion Criteria: 1. Patient requiring specialized IVF management as per the treating physician discretion. 2. Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure 3. Patients with ESRD on chronic dialysis 4. Patients with signs of shock (low SBP \<100 or MAP \< 65) and signs of hypo perfusion 5. Known or suspected pregnancy 6. Previously enrolled in this trial within the last 30 days 7. Enrolled in another trial study that interfered with fluid management 8. Unable to obtain IV access.

Treatments Being Tested

DRUG

Sodium Chloride (NaCl) 0.9 %

Keep vein open rate

DRUG

Sodium Chloride (NaCl) 0.9 %

IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements

Locations (2)

King Fahd Hospital of the University
Dammam, Eastern Province, Saudi Arabia
King Saud University Medical City
Riyadh, Saudi Arabia